Mereo Biopharma Group PLC
NASDAQ:MREO
EV/EBIT
Enterprise Value to EBIT
Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.
Market Cap | EV/EBIT | ||||
---|---|---|---|---|---|
UK |
Mereo Biopharma Group PLC
NASDAQ:MREO
|
434.8m USD | -9.8 | ||
US |
Abbvie Inc
NYSE:ABBV
|
284.3B USD | 19.6 | ||
US |
Amgen Inc
NASDAQ:AMGN
|
166B USD | 30.7 | ||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
107.5B USD | 25 | ||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
106.4B USD | 24.7 | ||
AU |
CSL Ltd
ASX:CSL
|
133.8B AUD | 26.7 | ||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
80.9B USD | 8.8 | ||
US |
Moderna Inc
NASDAQ:MRNA
|
47.9B USD | -7.8 | ||
US |
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | -55.8 | ||
US |
Biogen Inc
NASDAQ:BIIB
|
32.1B USD | 17.6 | ||
KR |
Celltrion Inc
KRX:068270
|
39.3T KRW | 61.8 |
EV/EBIT Forward Multiples
Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.